Immunotherapy before surgery for colon cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink colon cancer and improve outcomes. It is for people with a specific type of colon cancer that is planned for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have colon cancer that can be removed with surgery.
- Your cancer is a type called pMMR or MSS.
- You are generally healthy and able to care for yourself (ECOG 0 or 1).
- Your cancer is at least stage T3 or has spread to nearby lymph nodes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (pembrolizumab and porustobart) given before surgery for colon cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests immunotherapy plus chemotherapy given before surgery for colon cancer that hasn’t spread. It aims to shrink or control the tumor and improve outcomes in people whose tumor has certain immune/biologic features.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
Hear when a new Colon Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.